Abstract:Heat shock protein (Hsp) 90 is an ATP-dependent molecular chaperone that is exploited by malignant cells to support activated oncoproteins, including many cancer-associated kinases and transcription factors, and it is essential for oncogenic transformation. Originally viewed with skepticism, Hsp90 inhibitors are now being actively pursued by the pharmaceutical industry, with 17 agents having entered clinical trials. Investigators established Hsp90's druggability using the natural products geldanamycin and radicicol, which mimic the unusual ATP structure adopted in the chaperone's N-terminal nucleotide-binding pocket and cause potent and selective blockade of ATP binding/hydrolysis, inhibit chaperone function, deplete oncogenic clients, and show antitumor activity. Preclinical data obtained with these natural products have heightened interest in Hsp90 as a drug target, and 17-allylamino-17-demethoxygeldanamycin (17-AAG, tanespimycin) has shown clinical activity (as defined by Response Evaluation Criteria in Solid Tumors) in HER2+ breast cancer. Many optimized synthetic, small-molecule Hsp90 inhibitors from diverse chemotypes are now in clinical trials. Here, we review the discovery and development of Hsp90 inhibitors and assess their potential. There has been significant learning from studies of the basic biology of Hsp90, as well as translational drug development involving this chaperone, enhanced by the use of Hsp90 inhibitors as chemical probes. Success will likely lie in treating cancers that are addicted to particular driver oncogene products (e.g., HER2, ALK, EGFR, and BRAF) that are sensitive Hsp90 clients, as well as malignancies (especially multiple myeloma) in which buffering of proteotoxic stress is critical for survival. We discuss approaches for enhancing the effectiveness of Hsp90 inhibitors and highlight new chaperone and stress-response pathway targets, including HSF1 and Hsp70.

Targeting chaperones in transformed systems – a focus on Hsp90 and cancer

HSP90 and the chaperoning of cancer

Targeting HSP90 as a Novel Therapy for Cancer: Mechanistic Insights and Translational Relevance

Hsp90 Molecular Chaperone Inhibitors: Are We There Yet?

HSP90 as a new therapeutic target for cancer therapy: the story unfolds

Dynamically Shaping Chaperones. Allosteric Modulators of HSP90 Family as Regulatory Tools of Cell Metabolism in Neoplastic Progression

Targeting the HSP90–CDC37–kinase chaperone cycle: A promising therapeutic strategy for cancer

Current Understanding of HSP90 as a Novel Therapeutic Target: An Emerging Approach for the Treatment of Cancer

HSP90 inhibitors and cancer: Prospects for use in targeted therapies (Review)

Targeting the Hsp90-Cdc37-client protein interaction to disrupt Hsp90 chaperone machinery

The Hsp90 molecular chaperone: an open and shut case for treatment

HSP90 multi-functionality in cancer

New developments in Hsp90 inhibitors as anti-cancer therapeutics: Mechanisms, clinical perspective and more potential

HSP90 and Co-chaperones: Impact on Tumor Progression and Prospects for Molecular-Targeted Cancer Therapy

Targeting chaperone modifications: Innovative approaches to cancer treatment

HSP70 and HSP90 in Cancer: Cytosolic, Endoplasmic Reticulum and Mitochondrial Chaperones of Tumorigenesis

Targeting HSP90 for Cancer Therapy: Current Progress and Emerging Prospects

Inhibitors of the HSP90 Molecular Chaperone: Current Status

Targeting Heat-Shock Protein 90 in Cancer: An Update on Combination Therapy